NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. (Evidence Synthesis, No. 154.)
Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Show detailsTable 5The Effect of PSA-Based Screening on Prostate Cancer Incidence
| Study Reference Quality Rating | Location | N | Followup | Prostate Cancer Incidence | Stage or Risk Distribution at Diagnosis |
|---|---|---|---|---|---|
| PLCO Andriole, 201280 Fair | United States | 76,683‡ | 13.0 years (median) | IG: 11.1% (4250/38,340 men) 108.4 per 10,000 PY CG: 9.9% (3815/38,345 men) 97.1 per 10,000 PY RR=1.12 (95% CI, 1.07 to 1.17) | Stage 1: IG: 0.5% (19/4250 men) CG: 0.5% (17/3815 men) Stage 2: IG: 95.4% (4056/4250 men) CG: 94.0% (3584/3815 men) Stage 3: IG: 1.4% (58/4250 men) CG: 1.7% (65/3815 men) Stage 4: IG: 2.3% (96/4250 men) CG: 2.9% (111/3815 men) |
| ERSPC* Schroder, 201496 Buzzoni, 201583 Fair ERSPC Site-Specific Reports Sweden (Göteborg): Arnsrud Godtman, 201581 Spain: Lujan, 201489 Netherlands (Rotterdam): Roobol, 201392 Finland: Kilpelainen, 201387 | Europe (Netherlands, Belgium, Sweden, Finland, Italy, Spain, Switzerland, and France)† | 162,388 (core age group)§ | 13.0 years (median) | IG: 10.2% (7408/72,891 men) 95.5 per 10,000 PY CG: 6.8% (6107/89,352 men) 62.3 per 10,000 PY RR=1.57 (95% CI, 1.51 to 1.62) | Low Risk: IG: 60% (4442/7408 men) CG: 42% (2543/6107 men) RR=2.14 (95% CI, 2.03 to 2.25) Intermediate Risk: IG: 22% (1625/7408 men) CG: 28% (1711/6107 men) RR=1.24 (95% CI, 1.16 to 1.34) High Risk: IG: 7% (519/7408 men) CG: 11% (667/6107 men) RR=1.00 (95% CI, 0.89 to 1.13) Metastatic: IG: 3% (252/7408 men) CG: 10% (586/6107 men) RR=0.60 (95% CI, 0.52 to 0.70) |
| Sweden (Göteborg) | 20,000 | 18.0 years | IG: 14.0% (1396/10,000 men) CG: 9.6% (962/10,000 men) | Low Risk: IG: 50.0% (697/1396) CG: 26.3% (253/962) Intermediate Risk: IG: 33.6% (469/1396) CG: 37.4% (360/962) High Risk: IG: 9.7% (136/1396) CG: 17.6% (169/962) Advanced: IG: 2.7% (67/1396) CG: 12.2% (117/962) | |
| Spain | 4,276 | 15.2 years (median) | IG: 6.7% (161/2415 men) 47.8 per 10,000 PY CG: 4.3% (80/1861 men) 30.5 per 10,000 PY RR=1.57 (95% CI, 1.20 to 2.05) | NR | |
| Netherlands (Rotterdam) | 42,376 | 12.8 years (median) | IG: 12.7% (2674/20,985 men) CG: 6.8% (1430/20,917 men) | Low Risk: IG: 68.3% (1444/2113 men) CG: 42.3% (605/1430 men) Intermediate Risk: IG: 25.1% (531/2113 men) CG: 27.9% (399/1430 men) High Risk: IG: 5.5% (116/2113 men) CG: 13.0% (183/1430 men) Metastatic: IG: 0.8% (16/2113 men) CG: 12.8% (183/1430 men) | |
| Finland | 80,144 | 12.0 years (median) | IG: 9.0% (2883/31,866 men) 88.0 per 10,000 PY CG: 6.9% (3337/48,278 men) 66.0 per 10,000 PY HR= 1.34 (95% CI 1.27 to 1.40; p<0.001) | Low risk: IG: 61.5% (1774/2883 men) CG: 46.9% (1565/3337 men) HR=1.75 (95% CI 1.64 to 1.87; p<0.001) Moderate risk: IG: 25.0% (719/2883 men) CG: 32.2% (1076/3337 men) HR=1.03 (95% CI 0.94 to 1.14; p=0.48) High risk: IG: 13.2% (380/2883 men) CG: 20.5% (684/3337 men) HR=0.86 (95% CI 0.76 to 0.97; p=0.02) Advanced: HR=0.73 (95% CI, 0.64 to 0.82; p<0.001) |
- *
Main ERPSC trial includes most patients that are included in site-specific ERSPC reports
- †
Results for core age group only; excluded France due to incomplete followup
- ‡
Population sample sizes in the PLCO differ between the 13-year followup publication (Andriole, 2012; n=76,685) and the 11.5-year and 14.8-year followup (Andriole, 2009 and Pinsky, 2016; n=76,683)
- §
Population sample sizes in the ERSPC differ between the 9-year followup publication (Schroder, 2009; n=162,387) and the 11-year and 13-year followup (Schroder, 2012 and Schroder, 2014; n=162,388)
Abbreviations: CI=confidence interval; CG=control group; ERSPC=European Randomized Study of Screening for Prostate Cancer; HR=hazard ratio; IG=intervention group assigned to screening; PLCO=Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; RR=relative risk
- Table 5, The Effect of PSA-Based Screening on Prostate Cancer Incidence - Prosta...Table 5, The Effect of PSA-Based Screening on Prostate Cancer Incidence - Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force
- Homo sapiens cystatin E/M (CST6), mRNAHomo sapiens cystatin E/M (CST6), mRNAgi|1519241574|ref|NM_001323.4|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...